文献速递心境障碍

心境稳定剂和/或抗精神病药用于双相障碍维持期:随机对照试验的系统综述与网络Meta分析

Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
PubMed 文献 · Mol Psychiatry · 2020-11-11

主要结局为任何心境发作复发率,多数活性治疗优于安慰剂,但各治疗在疗效、耐受性和安全性上存在差异。

要点

  • 除卡马西平、拉莫三嗪+丙戊酸盐(无数据)和帕利哌酮外,所有活性治疗均优于安慰剂降低任何心境发作复发率。
  • 阿立哌唑+丙戊酸盐、拉莫三嗪、拉莫三嗪+丙戊酸盐、锂盐、奥氮平和喹硫平优于安慰剂降低抑郁发作复发率。
  • 除阿立哌唑+丙戊酸盐、卡马西平、拉莫三嗪和拉莫三嗪+丙戊酸盐外,所有活性治疗均优于安慰剂降低躁狂发作复发率。

核心结论

  • 多数抗精神病药和/或心境稳定剂单药或联合治疗在双相障碍维持期优于安慰剂,但各治疗在疗效、耐受性和安全性上存在差异。

主要发现

  • 除卡马西平、拉莫三嗪+丙戊酸盐(无数据)和帕利哌酮外,所有活性治疗均优于安慰剂降低任何心境发作复发率(RR-any)。
  • 阿立哌唑+丙戊酸盐、拉莫三嗪、拉莫三嗪+丙戊酸盐、锂盐、奥氮平和喹硫平优于安慰剂降低抑郁发作复发率(RR-dep)。
  • 除阿立哌唑+丙戊酸盐、卡马西平、拉莫三嗪和拉莫三嗪+丙戊酸盐外,所有活性治疗均优于安慰剂降低躁狂/轻躁狂/混合发作复发率(RR-mania)。
  • 阿塞那平、锂盐、奥氮平、喹硫平和丙戊酸盐优于安慰剂降低全因停药率。
  • 除奥氮平+锂盐/丙戊酸盐外,所有第二代抗精神病药+锂盐/丙戊酸盐联合治疗均优于安慰剂+锂盐/丙戊酸盐降低任何心境发作复发率。

关键数值与推荐

  • 主要结局为任何心境发作复发率(RR-any),次要结局包括抑郁发作复发率(RR-dep)、躁狂/轻躁狂/混合发作复发率(RR-mania)、停药、死亡率和个体不良事件,计算风险比和95%可信区间。

临床怎么用

  • 临床选择维持期药物时需综合评估疗效、耐受性和安全性,多数活性治疗可降低复发风险,但不同药物对抑郁或躁狂发作的预防作用存在差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We searched Embase, PubMed, and CENTRAL from inception until 22 May 2020 to investigate which antipsychotics and/or mood stabilizers are better for patients with bipolar disorder in the maintenance phase. We performed two categorical network meta-analyses. The first included monotherapy studies and studies in which the two drugs used were specified (i.e., aripiprazole, aripiprazole once monthly, aripiprazole+lamotrigine, aripiprazole+valproate, asenapine, carbamazepine, lamotrigine, lamotrigine+valproate, lithium, lithium+oxcarbazepine, lithium+valproate, olanzapine, paliperidone, quetiapine, risperidone long-acting injection, valproate, and placebo). The second included studies on second-generation antipsychotic combination therapies (SGAs) (i.e., aripiprazole, lurasidone, olanzapine, quetiapine, and ziprasidone) with lithium or valproate (LIT/VAL) compared with placebo with LIT/VAL. Outcomes were recurrence/relapse rate of any mood episode (RR-any, primary), depressive episode (RR-dep) and manic/hypomanic/mixed episode (RR-mania), discontinuation, mortality, and individual adverse events. Risk ratios and 95% credible interval were calculated. Forty-one randomized controlled trials were identified (n = 9821; mean study duration, 70.5 ± 36.6 weeks; percent female, 54.1%; mean age, 40.7 years). All active treatments other than carbamazepine, lamotrigine+valproate (no data) and paliperidone outperformed the placebo for RR-any. Aripiprazole+valproate, lamotrigine, lamotrigine+valproate, lithium, olanzapine, and quetiapine outperformed placebo for RR-dep. All active treatments, other than aripiprazole+valproate, carbamazepine, lamotrigine, and lamotrigine+valproate, outperformed placebo for RR-mania. Asenapine, lithium, olanzapine, quetiapine, and valproate outperformed placebo for all-cause discontinuation. All SGAs+LIT/VALs other than olanzapine+LIT/VAL outperformed placebo+LIT/VAL for RR-any. Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-dep. Aripiprazole+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for RR-mania. Lurasidone+LIT/VAL and quetiapine+LIT/VAL outperformed placebo+LIT/VAL for all-cause discontinuation. Treatment efficacy, tolerability, and safety profiles differed among treatments.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry. 2020. PMID: 33177610. doi:10.1038/s41380-020-00946-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。